Table 2 Clinical characteristics of patients with progestogen-related depression in the FDA adverse event reporting System Database (2004q1-2024q3).
Characteristics | Reports, n (%) |
|---|---|
Age | |
<18 | 149(2.3%) |
≥ 18, <45 | 4881(75.1%) |
≥ 45, <65 | 449(6.9%) |
65≤ | 16(0.2%) |
Not Specified | 1007(15.5%) |
Year | |
2004 | 52(0.8%) |
2005 | 57(0.9%) |
2006 | 53(0.8%) |
2007 | 59(0.9%) |
2008 | 172(2.6%) |
2009 | 167(2.6%) |
2010 | 153(2.4%) |
2011 | 253(3.9%) |
2012 | 225(3.5%) |
2013 | 286(4.4%) |
2014 | 728(11.2%) |
2015 | 790(12.2%) |
2016 | 465(7.2%) |
2017 | 1259(19.4%) |
2018 | 571(8.8%) |
2019 | 332(5.1%) |
2020 | 297(4.6%) |
2021 | 194(3.0%) |
2022 | 153(2.4%) |
2023 | 147(2.3%) |
2024 | 89(1.4%) |
Reporter | |
Consumer | 3954(60.8%) |
Health-professional | 2090(32.1%) |
Not Specified | 458(7.0%) |
Area | |
Africa | 8(0.1%) |
Asian | 12(0.2%) |
Europe | 1703(26.2%) |
North America | 3232(49.7%) |
Oceania | 25(0.4%) |
South America | 57(0.9%) |
Not Specified | 1465(22.5%) |
Drug | |
Levonorgestrel | 4812(74.0%) |
Etonogestrel | 1082(16.6%) |
Medroxyprogesterone | 461(7.1%) |
Hydroxyprogesterone | 107(1.6%) |
Progesterone | 29(0.4%) |
Desogestrel | 10(0.2%) |
Megestrol | 1(0.1%) |
